A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Idiopathic Short Stature (ISS).
Latest Information Update: 08 Sep 2025
At a glance
- Drugs Pegylated somatropin (Primary)
- Indications Short stature; Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
Most Recent Events
- 08 Sep 2025 Last checked against ClinicalTrials.gov record.
- 15 Jul 2025 Status changed from not yet recruiting to recruiting.
- 21 Apr 2025 New trial record